This study presents the development and preclinical evaluation of a novel osteotropic micronutrient complex (OMC) designed to enhance bone regeneration in osteopenic conditions. The formulation combines vitamin K2 (menaquinone-7), strontium citrate, fructoborate, and nano-hydroxyapatite to target multiple pathways of bone metabolism synergistically. Using an ovariectomized rat model of osteoporosis, we assessed the effects of OMC on bone mineral density (BMD), microarchitecture, biomechanical strength, and biochemical markers of bone turnover over a 12-week treatment period. The results demonstrate that OMC administration at 100 mg/kg significantly increased femoral BMD by 28.7% compared to vehicle controls, surpassing the effects of alendronate therapy. Micro-CT analysis revealed preservation of trabecular structure, with bone volume fraction (BV/TV) reaching 23.8±2.2% in the high-dose OMC group versus 14.7±1.8% in untreated controls. Biomechanical testing showed a 42.3% improvement in ultimate load capacity, while dynamic histomorphometry confirmed enhanced bone formation rates. Notably, OMC maintained balanced bone remodeling, reducing CTX levels by 38% without suppressing P1NP, in contrast to the pronounced antiresorptive effects of alendronate. Molecular analyses revealed upregulation of osteogenic markers (Runx2, Osterix) and improved collagen maturity, indicating superior bone quality. These findings highlight OMC as a promising alternative to conventional osteoporosis treatments, offering both anabolic and antiresorptive benefits through physiologically compatible mechanisms. The formulation’s safety profile and oral bioavailability further support its potential for clinical translation. Future studies should explore its efficacy in human trials and potential synergies with existing therapies.
